0001104659-24-078936.txt : 20240710 0001104659-24-078936.hdr.sgml : 20240710 20240710160521 ACCESSION NUMBER: 0001104659-24-078936 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240710 DATE AS OF CHANGE: 20240710 EFFECTIVENESS DATE: 20240710 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc. CENTRAL INDEX KEY: 0001651407 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 472568632 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-518335 FILM NUMBER: 241109984 BUSINESS ADDRESS: STREET 1: 95 SAWYER ROAD STREET 2: SUITE 110 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 781-652-4500 MAIL ADDRESS: STREET 1: 95 SAWYER ROAD STREET 2: SUITE 110 CITY: WALTHAM STATE: MA ZIP: 02453 D 1 primary_doc.xml X0708 D LIVE 0001651407 Checkpoint Therapeutics, Inc. 95 SAWYER ROAD SUITE 110 WALTHAM MA MASSACHUSETTS 02453 781-652-4500 DELAWARE None None Corporation true James F. Oliviero, III 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Executive Officer Director Neil Herskowitz 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Director Garrett Gray 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Executive Officer Michael Weiss 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Director Barry Salzman 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Director Christian Bechon 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Director Lindsay A. Rosenwald 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Director Amit Sharma 95 Sawyer Road Suite 110 Waltham MA MASSACHUSETTS 02453 Director Biotechnology Decline to Disclose 06b false 2024-07-02 false true true true false 0 H.C. Wainwright & Co., LLC 000000375 None None 430 Park Avenue New York NY NEW YORK 10022 FL FLORIDA NJ NEW JERSEY NY NEW YORK false Indefinite 0 Indefinite Checkpoint publicly sold $11,999,538 of common stock and equivalents and concurrently privately issued warrants and placement agent warrants pursuant to Rule 506(b) for up to 5,853,659 and up to 351,220 shares of common stock, respectively. false 1 0 0 Checkpoint paid approximately $900,000 in fees and expenses in connection with the public offering and concurrent private placement. Such fees included a $840,000.07 cash fee and $60,000 of non-accountable expenses. 0 Checkpoint has received no proceeds from the private placement and has received approximately $11,000,000 from the concurrent offering. false Checkpoint Therapeutics, Inc. /s/ James F. Oliviero James F. Oliviero President and Chief Executive Officer 2024-07-10